Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First Oral Cellular Factor Drug For Tumor In Phase III Trials

This article was originally published in PharmAsia News

Executive Summary

Shanghai Institute of Biochemistry and Cell Biology under the Chinese Academy of Sciences, Zhejiang University, Zhejiang Sci-Tech University and the Key Laboratory of Bioreactor and Biopharmacy of Zhejiang province recently announced they have successfully developed an orally administered granulocyte-macrophage colony-stimulating factor, which is currently in Phase III clinical trials. GM-CSF injection has been used clinically but it is inconvenient and patients suffer from side effects. The latest research, published by open-accessed online journal PloS One, shows that Chinese scientists have discovered a breakthrough method of oral absorption for the cellular factor drug, a world first in tumor bio-treatment. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts